+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10081(GLYATL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10081(GLYATL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GLYATL2 (Glycine-N-acyltransferase-like 2) antibody is a research tool used to study the GLYATL2 protein, a member of the glycine-N-acyltransferase family. This enzyme-like protein is implicated in the conjugation of glycine to acyl-CoA substrates, a process critical for detoxifying xenobiotics and metabolizing fatty acids. GLYATL2 is primarily expressed in the liver and kidneys, suggesting a role in hepatic and renal metabolic pathways. Its specific biological functions, however, remain less characterized compared to its homologs, such as GLYAT or GLYATL1.

Research using GLYATL2 antibodies focuses on elucidating its tissue distribution, subcellular localization, and interaction partners. Studies suggest potential links to metabolic disorders, cancer, and drug metabolism, though mechanistic insights are still emerging. For example, altered GLYATL2 expression has been observed in certain cancers, prompting investigations into its utility as a biomarker or therapeutic target.

Commercially available GLYATL2 antibodies are typically developed in rabbit or mouse hosts, validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Challenges include ensuring specificity due to sequence homology within the GLYAT family. Recent advances in antibody validation techniques, such as CRISPR-based knockout controls, have improved reliability. These tools are vital for advancing understanding of GLYATL2's physiological and pathological roles, bridging gaps in metabolic and disease-related research.